ASP Isotopes Quantitative Scenario Analysis
1/24/26
SEQH Capital Research
ASP Isotopes (ASPI): Tear Sheet
January 24, 2026
High-Level Thesis
ASP Isotopes (NASDAQ: ASPI) is an advanced materials company using proprietary enrichment technologies to target three multi‑billion‑dollar markets: medical isotopes, semiconductor isotopes, and nuclear fuel via its Quantum Leap Energy (QLE) subsidiary. Our work indicates ASPI is significantly undervalued, with an 18‑month Strong Buy price target range of 40–50 dollars per share supported by Monte Carlo, DCF, and Sum‑of‑the‑Parts analysis.
ASPI at a Glance
Current share price: 8.10 dollars.
18‑month mean target (model output): 15.54 dollars.
SEQH 18‑month target range: 40–50 dollars per share.
Market cap: approximately 897.8 million dollars.
TTM revenue: 8.38 million dollars.
2030 base‑case revenue: 87.9 million dollars; SEQH Target scenario: 260+ million dollars.
Business verticals:
Medical isotopes (diagnostic imaging, oncology).
Semiconductor isotopes (Silicon‑28 for quantum and advanced chips).
Nuclear energy/QLE (HALEU and enriched uranium for SMRs and advanced reactors).
Technology & Competitive Edge
ASPI’s core edge is its dual proprietary enrichment platforms:
Aerodynamic Separation Process (ASP): stationary wall centrifuge enabling efficient separation of light isotopes at lower capex and faster deployment than legacy methods.
Quantum Enrichment (QE): laser‑based enrichment with high selectivity and efficiency, especially for uranium and QLE’s HALEU ambitions.
These technologies allow potential construction of enrichment facilities at a fraction of the cost and time of traditional gaseous diffusion and centrifuge plants, positioning ASPI as a differentiated supplier across medical, semiconductor, and nuclear markets.
QLE Spinoff: Core Catalyst
The planned spinoff and IPO of Quantum Leap Energy is the central value‑unlocking catalyst in our thesis.
QLE focus: HALEU and enriched uranium products for SMRs and advanced reactor designs, where most designs require HALEU that is not yet widely available commercially.
Market context:
Global enrichment market estimated at over 14 billion dollars in 2025, projected to exceed 22 billion dollars by 2030 at a 9.25% CAGR.
HALEU and SMR sub‑segments growing even faster at 12.3% and 11.8% CAGR, respectively.
Russia currently dominates a large share of the broader isotope and enrichment market; Western governments are funding domestic alternatives.
Spinoff valuation highlights (base case):
QLE revenue of 50 million dollars by 2027, valued at 25x revenue, implies a 1.25 billion dollar standalone valuation.
This scenario points to roughly 70% upside in combined shareholder value versus ASPI’s current market cap.
Even after distributing 80% of QLE, the remaining ASPI (core business plus 20% QLE stake) screens at an implied 4.72 dollar share price with additional upside as medical and semiconductor businesses mature.
In more optimistic cases, where QLE scales faster and is valued closer to nuclear tech peers such as Oklo, total value creation could exceed 100–170%.
Market Opportunity & Growth
Key market drivers:
Geopolitical imperative to onshore nuclear fuel supply and reduce dependence on Russia’s dominant enrichment position.
Strong policy and funding support from Western governments for domestic enrichment and advanced nuclear infrastructure.
Secular demand growth from:
SMRs and advanced reactors requiring HALEU.
Quantum computing and high‑end semiconductors demanding ultra‑pure isotopes.
Nuclear medicine expansion, with the global medical isotope market expected to grow from 5.1 billion dollars in 2022 to 11.4 billion dollars by 2032.
Revenue and margin trajectory (base case):
Revenues projected to grow from 8.4 million dollars (TTM) to about 87.9 million dollars by 2030, with SEQH Target scenario above 260 million dollars.
Gross margins expanding from 32% to 48%, operating margins reaching around 15% by 2030 as scale is achieved.
Quantitative Work & Upside Distribution
Our quantitative framework includes multi‑scenario revenue and margin modeling plus an 18‑month Monte Carlo simulation with 10,000 unique price paths.
Key simulation outputs:
Probability of reaching 40 dollars: 8.6%.
Probability of reaching 50 dollars: 6.3%.
95th percentile outcome: 59.82 dollars.
The median outcome is more modest, but the tail outcomes demonstrate a meaningful, statistically supported chance of achieving and exceeding our target range, consistent with a high‑risk, high‑reward profile.
Risks & Mitigants
Principal risks:
Execution risk on scaling and commercial deployment of ASP and QE technologies.
Regulatory and licensing risk in nuclear, potentially impacting QLE timelines.
Capital intensity and the need for additional funding, with dilution risk for common shareholders.
Mitigants:
Initial commercial production underway and key partnerships in place.
Active engagement with regulators and strong policy backing for domestic enrichment.
QLE IPO expected to provide a major capital infusion with relatively attractive financing versus repeated dilutive equity raises at the parent level.
SEQH View
We view ASP Isotopes as a compelling asymmetric opportunity at the intersection of nuclear renaissance, quantum/semiconductor advancement, and nuclear medicine growth. Our SOTP‑based 18‑month price target range of 40–50 dollars reflects both the upside from the QLE spinoff and the maturation of the core medical and semiconductor businesses, while acknowledging the elevated execution and regulatory risks inherent in a development‑stage story. We reiterate a Strong Buy recommendation.
Full Report (Paid Subscribers Only)
The full ASP Isotopes quantitative report includes:
Detailed multi‑scenario revenue and margin models.
Complete DCF, SOTP, and Monte Carlo methodology and outputs.
QLE spinoff valuation trees and sensitivity work.
Competitive landscape analysis across medical, semiconductor, and nuclear markets.
Risk scenarios, stress testing, and implementation guidance.
